Shree Ganesh Remedies

Shree Ganesh Remedies reported Q4 FY26 revenue of ₹33.2 croreCurrent reported value: ₹33.2 crore. No comparable prior figure is available in the source record., up 36% YoYCurrent reported value: 36% YoY. No comparable prior figure is available in the source record., driven by recovery from deferred shipments and improved execution. EBITDA at ₹11.37 croreCurrent reported value: ₹11.37 crore. No comparable prior figure is available in the source record. grew 15% YoY, but margins contracted to 34.3%Current reported value: 34.3%. No comparable prior figure is available in the source record. from 40.4% due to product mix and raw material volatility. PAT declined 5% YoY to ₹6.27Current reported value: 6.27. No comparable prior figure is available in the source record. crore. Management characterized FY26 as a consolidation year, with groundwork laid for future growth. Key developments include successful pilot trials for graphene projects in Europe and Japan, progressing to commercial trials, and Block 7 expansion on track for Q2 FY27 commercial production. Guidance for FY27 is cautiously optimistic, expecting gradual momentum improvement and graphene traction. Risks include prolonged geopolitical uncertainty, regulatory approval delays, and domestic pricing pressure. The company remains focused on niche specialty chemicals and CDMO, avoiding commoditized segments.